Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - budesonid - inhalationspulver - 400 mikrogram/dosis

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - budesonid - næsespray, suspension - 64 mikrogram/dosis

Европска Унија - Дански - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - vylaer spiromax er indiceret hos voksne kun 18 år og ældre. asthmavylaer spiromax er angivet i den almindelige behandling af astma, hvor anvendelsen af en kombination (inhaleret binyrebarkhormon og langtidsvirkende β2 adrenoceptor agonist) er hensigtsmæssige:i patienter ikke er tilstrækkeligt kontrolleret med inhalerede kortikosteroider og "efter behov" inhaleret korttidsvirkende β2 adrenoceptor-agonister. orin patienter, der allerede er tilstrækkeligt kontrolleret på både inhaleret binyrebarkhormon og langtidsvirkende β2 adrenoceptor-agonister. copdsymptomatic behandling af patienter med svær kol (fev1 < 50% forventet normale) og en historie med gentagne eksacerbationer, der har betydelige symptomer på trods af regelmæssig behandling med langtidsvirkende bronkodilatatorer.

Европска Унија - Дански - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Европска Унија - Дански - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Европска Унија - Дански - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmachemie b.v. - budesonid - inhalationspulver, hård kapsel - 200 mikrogram

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmachemie b.v. - budesonid - inhalationspulver, hård kapsel - 400 mikrogram

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - budesonid - inhalationspulver, hård kapsel - 400 mikrogram

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - budesonid - inhalationsvæske til nebulisator, suspension - 0,5 mg/ml